

New Hampshire State Senator Lou D'Allesandro State House, Room 117 107 North Main Street Concord, NH 03301

January 17, 2020

Dear Senator D'Allesandro,

On behalf of the Asthma and Allergy Foundation of America (AAFA) and the more than 32 million Americans living with life-threatening food allergies, I am writing to express AAFA's strong support for S.B. 642, an act relative to the administration of epinephrine.

AAFA is the leading patient organization for people with asthma and allergies, and the oldest asthma and allergy patient organization in the world. Kids With Food Allergies, a division of AAFA, offers tools, education, and community to families and children coping with food allergies across the country.

Food allergies are affecting a growing number of American children and adults. Between four and six percent of all children in the U.S. have food allergies. Exposure to the allergen can cause severe reactions, including anaphylaxis and, in rare cases, death. Because there is no cure for food allergies, awareness and preparedness are key for protecting health and saving lives.

Epinephrine is the only treatment for anaphylaxis and is only available with a prescription. Children and adults who have severe food allergies need epinephrine with them at all times to promptly treat anaphylaxis. In situations where a person does not have access to epinephrine (they may not have their prescribed auto-injector with them, or they could be experiencing their first-ever reaction to a certain allergen), the reaction can become life-threatening. The protection S.B.642 provides by allowing trained staff or agents of authorized entities to treat someone suffering anaphylaxis, even for their very first allergic reaction, is life-saving.

One preventable death is one too many. Thank you very much for your leadership on this legislation. We are grateful for your concern for the safety of those managing food allergies.

Sincerely,

Kenneth Mendez President and Chief Executive Officer Asthma and Allergy Foundation of America



New Hampshire State Senator Tom Sherman State House, Room 107 107 North Main Street Concord, NH 03301

January 17, 2020

Dear Senator Sherman,

On behalf of the Asthma and Allergy Foundation of America (AAFA) and the more than 32 million Americans living with life-threatening food allergies, I am writing to express AAFA's strong support for S.B. 642, an act relative to the administration of epinephrine.

AAFA is the leading patient organization for people with asthma and allergies, and the oldest asthma and allergy patient organization in the world. Kids With Food Allergies, a division of AAFA, offers tools, education, and community to families and children coping with food allergies across the country.

Food allergies are affecting a growing number of American children and adults. Between four and six percent of all children in the U.S. have food allergies. Exposure to the allergen can cause severe reactions, including anaphylaxis and, in rare cases, death. Because there is no cure for food allergies, awareness and preparedness are key for protecting health and saving lives.

Epinephrine is the only treatment for anaphylaxis and is only available with a prescription. Children and adults who have severe food allergies need epinephrine with them at all times to promptly treat anaphylaxis. In situations where a person does not have access to epinephrine (they may not have their prescribed auto-injector with them, or they could be experiencing their first-ever reaction to a certain allergen), the reaction can become life-threatening. The protection S.B.642 provides by allowing trained staff or agents of authorized entities to treat someone suffering anaphylaxis, even for their very first allergic reaction, is life-saving.

One preventable death is one too many. Thank you very much for your time and consideration. We are grateful for your concern for the safety of those managing food allergies.

Sincerely,

Kenneth Mendez President and Chief Executive Officer Asthma and Allergy Foundation of America



New Hampshire State Senator Martha Fuller Clark State House, Room 302 107 North Main Street Concord, NH 03301

January 17, 2020

Dear Senator Fuller Clark,

On behalf of the Asthma and Allergy Foundation of America (AAFA) and the more than 32 million Americans living with life-threatening food allergies, I am writing to express AAFA's strong support for S.B. 642, an act relative to the administration of epinephrine.

AAFA is the leading patient organization for people with asthma and allergies, and the oldest asthma and allergy patient organization in the world. Kids With Food Allergies, a division of AAFA, offers tools, education, and community to families and children coping with food allergies across the country.

Food allergies are affecting a growing number of American children and adults. Between four and six percent of all children in the U.S. have food allergies. Exposure to the allergen can cause severe reactions, including anaphylaxis and, in rare cases, death. Because there is no cure for food allergies, awareness and preparedness are key for protecting health and saving lives.

Epinephrine is the only treatment for anaphylaxis and is only available with a prescription. Children and adults who have severe food allergies need epinephrine with them at all times to promptly treat anaphylaxis. In situations where a person does not have access to epinephrine (they may not have their prescribed auto-injector with them, or they could be experiencing their first-ever reaction to a certain allergen), the reaction can become life-threatening. The protection S.B.642 provides by allowing trained staff or agents of authorized entities to treat someone suffering anaphylaxis, even for their very first allergic reaction, is life-saving.

One preventable death is one too many. Thank you very much for your time and consideration. We are grateful for your concern for the safety of those managing food allergies.

Sincerely,

Kenneth Mendez President and Chief Executive Officer Asthma and Allergy Foundation of America